CD274 and neoplasm: Specifically, anti-angiogenic medications optimize the tumor microenvironment, mitigate the suppressive effects of the tumor on immune cells, and enhance the infiltration and functionality of immune cells, thereby intensifying the immunotherapeutic effect of PD-(L)1 inhibitors.